NASA Awards $2.9M for In-Space Stem Cell Therapy Production to Cedars-Sinai

Contract Overview

Contract Amount: $2,930,391 ($2.9M)

Contractor: Cedars-Sinai Medical Center

Awarding Agency: National Aeronautics and Space Administration

Start Date: 2022-09-21

End Date: 2026-12-30

Contract Duration: 1,561 days

Daily Burn Rate: $1.9K/day

Competition Type: NOT COMPETED UNDER SAP

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: R&D

Official Description: IN-SPACE PRODUCTION OF STEM CELL THERAPIES

Place of Performance

Location: WEST HOLLYWOOD, LOS ANGELES County, CALIFORNIA, 90048

State: California Government Spending

Plain-Language Summary

National Aeronautics and Space Administration obligated $2.9 million to CEDARS-SINAI MEDICAL CENTER for work described as: IN-SPACE PRODUCTION OF STEM CELL THERAPIES Key points: 1. Focus on advanced biomedical research with potential for significant health breakthroughs. 2. Limited competition raises questions about price discovery and potential cost efficiencies. 3. High-risk, high-reward project with long-term implications for space exploration and medicine. 4. Sector is R&D, specifically life sciences, a critical area for future innovation.

Value Assessment

Rating: fair

The contract value of $2.9M over approximately 4 years appears reasonable for specialized R&D. However, without a competitive process, it's difficult to benchmark against similar contracts or assess if the best possible price was achieved.

Cost Per Unit: N/A

Competition Analysis

Competition Level: limited

The contract was not competed under Simplified Acquisition Procedures (SAP), indicating a potential limitation in competition. This lack of broad competition may have impacted the government's ability to secure the most advantageous pricing.

Taxpayer Impact: Taxpayer funds are supporting cutting-edge research. While the potential benefits are high, the lack of competition warrants scrutiny to ensure value for money.

Public Impact

Advancement of medical treatments that could benefit astronauts and potentially patients on Earth. Pioneering new manufacturing capabilities in the unique environment of space. Potential for long-term cost savings in healthcare through novel therapies.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

  • Limited competition
  • Long project duration
  • High R&D risk

Positive Signals

  • Innovative technology development
  • Potential for significant health impact
  • Supports space exploration goals

Sector Analysis

This contract falls within the Research and Development sector, specifically life sciences. Spending in this area is crucial for innovation but often involves higher risk and longer timelines compared to more established sectors.

Small Business Impact

The data indicates this contract was awarded to Cedars-Sinai Medical Center, a large research institution. There is no explicit indication of small business involvement in this specific award.

Oversight & Accountability

The award was made by NASA, a federal agency with established oversight mechanisms. However, the limited competition aspect suggests a need for thorough review of the justification for sole-source or limited-source procurement.

Related Government Programs

  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
  • National Aeronautics and Space Administration Contracting
  • National Aeronautics and Space Administration Programs

Risk Flags

  • Lack of full and open competition
  • Long contract duration with potential for cost overruns
  • High inherent risk in R&D projects
  • Uncertainty of successful translation to terrestrial applications

Tags

research-and-development-in-the-physical, national-aeronautics-and-space-administr, ca, purchase-order, 1m-plus

Frequently Asked Questions

What is this federal contract paying for?

National Aeronautics and Space Administration awarded $2.9 million to CEDARS-SINAI MEDICAL CENTER. IN-SPACE PRODUCTION OF STEM CELL THERAPIES

Who is the contractor on this award?

The obligated recipient is CEDARS-SINAI MEDICAL CENTER.

Which agency awarded this contract?

Awarding agency: National Aeronautics and Space Administration (National Aeronautics and Space Administration).

What is the total obligated amount?

The obligated amount is $2.9 million.

What is the period of performance?

Start: 2022-09-21. End: 2026-12-30.

What is the projected long-term impact of in-space stem cell production on terrestrial healthcare?

In-space stem cell production could lead to breakthroughs in regenerative medicine by leveraging microgravity for enhanced cell growth and differentiation. This may result in more effective therapies for diseases like Parkinson's, heart disease, and spinal cord injuries, potentially reducing long-term healthcare costs and improving patient outcomes on Earth.

What are the primary risks associated with the limited competition for this R&D contract?

The primary risks of limited competition include potentially higher costs due to the absence of market pressure, a reduced pool of innovative solutions, and the possibility that the government did not secure the most advantageous terms. It also raises concerns about fairness and transparency in the procurement process.

How will the effectiveness of this R&D investment be measured and ensured?

Effectiveness will likely be measured through milestone achievements, scientific publications, successful cell culture and differentiation in space, and the development of viable therapeutic candidates. NASA will monitor progress against the contract's technical objectives and deliverables, with potential for follow-on funding based on demonstrated success.

Industry Classification

NAICS: Professional, Scientific, and Technical ServicesScientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENTSpace R&D Services

Competition & Pricing

Extent Competed: NOT COMPETED UNDER SAP

Solicitation Procedures: SIMPLIFIED ACQUISITION

Solicitation ID: NNJ13ZBG001N

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 8700 BEVERLY BLVD, WEST HOLLYWOOD, CA, 90048

Business Categories: Category Business, Corporate Entity Tax Exempt, Hospital, Nonprofit Organization, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $3,530,300

Exercised Options: $3,530,300

Current Obligation: $2,930,391

Actual Outlays: $1,880,391

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Timeline

Start Date: 2022-09-21

Current End Date: 2026-12-30

Potential End Date: 2026-12-30 00:00:00

Last Modified: 2026-01-27

Other National Aeronautics and Space Administration Contracts

View all National Aeronautics and Space Administration contracts →

Explore Related Government Spending